BI 764532
Boehringer Ingelheim
['breast', 'bcsm', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)']
check out the 10 yrs results of shorter trastuzumab duration (vs 1 year) for her2+ breast cancer in the shorther trial! join us at e451 at #asco2023 today! #bcsm 
MD, Medical Oncologist and Clinical/Translational Researcher